Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Deferred Taxes (2021 - 2024)

Entera Bio has reported Deferred Taxes over the past 4 years, most recently at $14000.0 for Q4 2024.

  • For the quarter ending Q4 2024, Deferred Taxes changed N/A year-over-year to $14000.0, compared with a TTM value of $43000.0 through Dec 2024, up 48.28%, and an annual FY2024 reading of $14000.0, down 51.72% over the prior year.
  • Deferred Taxes came in at $14000.0 for Q4 2024, down from $29000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $214000.0 in Q3 2022 to a low of -$57000.0 in Q2 2021.
  • Median Deferred Taxes over the past 4 years was -$31500.0 (2022), compared with a mean of $0.0.
  • The sharpest move saw Deferred Taxes soared 475.44% in 2022, then tumbled 86.45% in 2023.
  • Over 4 years, Deferred Taxes stood at -$51000.0 in 2021, then soared by 145.1% to $23000.0 in 2022, then rose by 26.09% to $29000.0 in 2023, then plummeted by 51.72% to $14000.0 in 2024.
  • Per Business Quant, the three most recent readings for ENTX's Deferred Taxes are $14000.0 (Q4 2024), $29000.0 (Q3 2023), and $23000.0 (Q4 2022).